Published in Health Business Week, February 9th, 2007
"The results of this study suggest that microsomal triglyceride transfer protein (MTP) inhibition with AEGR-733 is a highly effective and potentially promising agent to treat these high-risk, hard-to-treat patients, for whom there are few effective treatment options. It may also have applicability in a much broader population of patients - those who are not sufficiently clinically responsive to standard therapy or are intolerant of statins," said Daniel J....
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.